Summit Financial LLC Takes Position in DaVita Inc. $DVA

Key Points

• Summit Financial LLC has acquired a new stake in DaVita Inc., purchasing 3,502 shares valued at approximately $536,000.
• Barclays has reduced its target price for DaVita from $169.00 to $160.00, while Wall Street Zen upgraded the rating to a "buy."
• DaVita reported earnings of $2.95 per share for the last quarter, exceeding analysts' expectations, with revenues of $3.38 billion, marking a 6.1% year-over-year increase.

Summit Financial LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,502 shares of the company's stock, valued at approximately $536,000.

Several other large investors have also made changes to their positions in DVA. Capital Fund Management S.A. raised its position in DaVita by 182.1% in the first quarter. Capital Fund Management S.A. now owns 15,279 shares of the company's stock valued at $2,337,000 after purchasing an additional 33,879 shares during the period. Humankind Investments LLC acquired a new position in shares of DaVita during the first quarter worth approximately $216,000. Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in DaVita by 3.6% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 17,956 shares of the company's stock worth $2,747,000 after purchasing an additional 626 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of DaVita by 207.9% in the 1st quarter. Wellington Management Group LLP now owns 8,348 shares of the company's stock worth $1,277,000 after acquiring an additional 5,637 shares during the last quarter. Finally, Northern Trust Corp raised its stake in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock valued at $136,240,000 after purchasing an additional 149,858 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Truist Financial set a $148.00 target price on shares of DaVita in a report on Friday, August 8th. Finally, Barclays cut their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $164.00.

DaVita Stock Performance

DVA stock traded down $1.55 during mid-day trading on Thursday, hitting $136.01. The company had a trading volume of 990,239 shares, compared to its average volume of 858,249. The stock's fifty day moving average price is $139.70 and its two-hundred day moving average price is $143.37. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The firm has a market cap of $9.72 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 0.99 and a beta of 1.09. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the firm posted $2.00 EPS. DaVita's revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.50% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.